A recent placebo-controlled trial has revealed that a single dose of psilocybin, the active compound in magic mushrooms, significantly alleviates symptoms of obsessive-compulsive disorder (OCD). Remarkably, these effects last for at least 12 weeks, suggesting psilocybin could offer enduring relief for OCD sufferers.

“Investing in experiences like travel can disrupt patterns of obsessive thinking and behavior,” notes Dr. David Nutt from Imperial College London, who wasn’t part of the study. “The essence of OCD treatment is to guide individuals towards behavioral change—like reducing the number of times they check the lights from 15 to 2.”

Approximately 1-3% of the population suffers from OCD, a condition marked by distressing obsessions and compulsive behaviors that can severely affect daily life. Conventional treatments often involve talk therapy and antidepressants; however, 40-60% of OCD patients fail to respond to these options.

Other psychedelics, including psilocybin and ketamine, have demonstrated therapeutic potential for various mental health disorders. To explore these possibilities, Dr. Christopher Pittenger at Yale University launched the first randomized, placebo-controlled study focused on psilocybin’s effects on OCD.

The research involved 28 adults with an average of 20 years of OCD experience who had previously undergone at least two failed treatment attempts. Participants assessed their symptom severity using a standard scale ranging from 0 to 40 and were randomly assigned to receive either a single oral dose of psilocybin (0.25 milligrams per kilogram) or niacin (250 milligrams), serving as a placebo.

The psilocybin dose was sufficient to induce a psychedelic experience, often associated with profound changes in perception, cognition, and emotion. “The intensity varies, but it’s generally quite strong,” remarks Pittenger.

Following 48 hours, participants who received psilocybin reported an average symptom score reduction of 9.76 points, while those given niacin showed minimal changes. “The rapid and enduring improvements after a single psilocybin dose are astonishing,” states Dr. Alex Kwan from Cornell University.

After one week, around 70% of participants who took psilocybin experienced a 35% decrease in symptom scores, and this effect persisted through the 12-week follow-up. “Psilocybin outperforms traditional OCD medications in both efficacy and speed,” says Nutt, who was involved in a separate clinical trial that lacked a placebo control. Research indicates that low doses of psilocybin can significantly diminish OCD symptoms.

Kwan suggests that the positive outcomes in individuals who have previously undergone several standard treatments point to psilocybin’s unique influence on the brain, though the precise mechanisms behind its efficacy in managing OCD remain unclear. “Understanding the biology behind its effects could revolutionize the treatment strategies not only for OCD but also for various mental health disorders,” he notes.

One hypothesis suggests that psilocybin enhances brain plasticity, potentially weakening entrenched thoughts that typically dominate an individual’s mindset. This flexibility is a critical challenge with all psychedelic substances, according to Nutt, who previously demonstrated that a single dose of the psychedelic DMT alleviated depression symptoms. “Individuals experiencing depressive thoughts found their thinking became more adaptable post-psychedelic experience,” he states.

Another theory posits that psilocybin recalibrates the brain’s default mode network, influencing areas linked to rumination and self-awareness, according to Pittenger. Research has also shown that a single psilocybin dose can enhance mental health by rewiring neural connections and reducing inflammation.

However, safety concerns regarding psilocybin use have emerged. In a Yale University study, a participant with a history of suicidal thoughts began to actively plan suicide during the trial. Although this risk was later mitigated through standard monitoring, Pittenger emphasizes the necessity for stringent clinical safeguards when administering psilocybin in medical contexts. Comprehensive trials are also needed to validate the drug’s efficacy, safety, optimal dosing, as well as to identify ideal candidates and those at increased risk, he adds.

A recurring challenge in psychedelic research is that participants’ experiences can often reveal whether they received the active drug or placebo. To combat this, researchers administered niacin, which can provoke sensations like facial flushing and elevated heart rate. However, many participants still discerned their treatment, according to Pittenger. “As with most studies of this nature, this presents a limitation,” he concludes.

If you’re in need of support, reach out to: British Samaritans at 116123; US 988 Suicide and Crisis Lifeline at 988; or explore hotlines available in other countries.